Latest News and Press Releases

REDMOND, Wash., Aug. 11, 2009 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a development-stage biopharmaceutical company, whose research and development efforts have focused on the...

REDMOND, Wash., May 14, 2009 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a development-stage biopharmaceutical company focused on the development of new treatments for vascular...

REDMOND, Wash., March 6, 2009 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a biopharmaceutical company focused on the development of new treatments for vascular disorders leveraging its...

TUCSON, Ariz., Nov. 13, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a biopharmaceutical company focused on the development of new treatments for vascular disorders leveraging its...

TUCSON, Ariz., Oct. 17, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX) today announced that it has been advised by The Nasdaq Stock Market ("NASDAQ") pursuant to Marketplace Rule 4300...

TUCSON, Ariz., Sept. 24, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX) today announced that it has divested its urokinase business to Microbix Biosystems, Inc. (TSX:MBX). Through...

TUCSON, Ariz., Aug. 26, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX) today announced that it received a NASDAQ Staff Deficiency Letter on August 20, 2008 indicating, based on the...

TUCSON, Ariz., Aug. 14, 2008 (PRIME NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX), a biopharmaceutical company with a commercial product, urokinase, and a research and development program...

TUCSON, Ariz., Nov. 4, 2004 (PRIMEZONE) -- ImaRx Therapeutics, Inc. (www.imarx.com) is pleased to announce that Jeane M. Tsutsui, MD of the University of Nebraska Medical Center will be presenting...

TUCSON, Ariz., Nov. 1, 2004 (PRIMEZONE) -- Terry Matsunaga, PharmD, Ph.D., Vice President of Research for ImaRx Therapeutics, Inc. (www.imarx.com) received the Excellence in Biotechnology Award for...